PT3198033T - Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr - Google Patents

Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr

Info

Publication number: PT3198033T
Authority: PT; Portugal
Prior art keywords: fgfr; responsive; treatment; cancer patients; mutant gene
Prior art date: 2014-09-26

Application number

PT157821091T

Other languages

English (en)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-26

Filing date

2015-09-18

Publication date

2022-05-25

2015-09-18 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2022-05-25 Publication of PT3198033T publication Critical patent/PT3198033T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Wood Science & Technology (AREA)
Pathology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Microbiology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

PT157821091T 2014-09-26 2015-09-18 Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr PT3198033T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462056159P	2014-09-26	2014-09-26

Publications (1)

Publication Number	Publication Date
PT3198033T true PT3198033T (pt)	2022-05-25

Family

ID=54337343

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT157821091T PT3198033T (pt)	2014-09-26	2015-09-18	Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr

Country Status (38)

Country	Link
US (3)	US20160090633A1 (pt)
EP (2)	EP4063516A1 (pt)
JP (4)	JP6766037B2 (pt)
KR (2)	KR20220162823A (pt)
CN (2)	CN107002141B (pt)
AR (1)	AR102345A1 (pt)
AU (2)	AU2015321626B2 (pt)
CA (1)	CA2962075A1 (pt)
CO (1)	CO2017003528A2 (pt)
CR (1)	CR20170104A (pt)
CY (1)	CY1125190T1 (pt)
DK (1)	DK3198033T3 (pt)
EA (1)	EA037920B1 (pt)
EC (1)	ECSP17025787A (pt)
ES (1)	ES2912567T3 (pt)
GT (1)	GT201700059A (pt)
HR (1)	HRP20220496T1 (pt)
HU (1)	HUE058219T2 (pt)
IL (2)	IL251264B (pt)
JO (1)	JO3681B1 (pt)
LT (1)	LT3198033T (pt)
MA (1)	MA40761B1 (pt)
MX (2)	MX2017003954A (pt)
MY (1)	MY194567A (pt)
NI (1)	NI201700035A (pt)
PH (1)	PH12017500556A1 (pt)
PL (1)	PL3198033T3 (pt)
PT (1)	PT3198033T (pt)
RS (1)	RS63178B1 (pt)
SG (1)	SG11201702381QA (pt)
SI (1)	SI3198033T1 (pt)
SM (1)	SMT202200177T1 (pt)
SV (1)	SV2017005415A (pt)
TW (1)	TWI706136B (pt)
UA (1)	UA122564C2 (pt)
UY (1)	UY36325A (pt)
WO (1)	WO2016048833A2 (pt)
ZA (1)	ZA201702899B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101942148B1 (ko)	2012-09-27	2019-01-24	추가이 세이야쿠 가부시키가이샤	Ｆｇｆｒ３ 융합 유전자 및 그것을 표적으로 하는 의약
US10048277B2 (en)	2014-01-24	2018-08-14	Japanese Foundation For Cancer Research	Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof
MA55696A (fr)	2014-03-26	2022-02-23	Astex Therapeutics Ltd	Combinaisons
UA122564C2 (uk)	2014-09-26	2020-12-10	Янссен Фармацевтика Нв	Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) *	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
MA43807A (fr) *	2016-03-04	2018-11-28	Taiho Pharmaceutical Co Ltd	Préparation et composition de traitement de tumeurs malignes
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
JOP20190280A1 (ar)	2017-06-02	2019-12-02	Janssen Pharmaceutica Nv	مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
JP6896104B2 (ja)	2018-07-27	2021-06-30	ゼプトライフテクノロジー，エルエルシーＺｅｐｔｏＬｉｆｅＴｅｃｈｎｏｌｏｇｙ，Ｌｌｃ	Ｇｍｒによるバイオマーカの検出システムおよび方法
AU2019342289A1 (en) *	2018-09-21	2021-03-18	Janssen Pharmaceutica Nv	Treatment of cholangiocarcinoma
JP2022527482A (ja)	2019-03-29	2022-06-02	ヤンセンファーマシューティカエヌ．ベー．	尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
CN113645974A (zh)	2019-03-29	2021-11-12	詹森药业有限公司	用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
US20220233537A1 (en) *	2019-05-31	2022-07-28	Qed Therapeutics, Inc.	Methods of treating urinary system cancers
CN110241183B (zh) *	2019-06-13	2022-10-28	南京世和基因生物技术股份有限公司	一种fgfr融合基因的检测方法、试剂盒以及探针库
US20220307078A1 (en) *	2019-09-09	2022-09-29	Zepto Life Technology, LLC	Systems and methods for detecting genetic variation in nucleic acids
AU2020352668A1 (en)	2019-09-26	2022-03-31	Janssen Pharmaceutica Nv	Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
TW202140012A (zh)	2020-02-12	2021-11-01	比利時商健生藥品公司	用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
EP4103185A1 (en)	2020-02-12	2022-12-21	Janssen Pharmaceutica NV	Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
MX2022012982A (es) *	2020-04-15	2023-03-06	Alkermes Pharma Ireland Ltd	Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis.
CN111440790A (zh) *	2020-05-08	2020-07-24	公安部物证鉴定中心	唾液斑迹dna和rna同时提取的方法
US20230321087A1 (en)	2020-09-14	2023-10-12	Janssen Pharmaceutica Nv	Fgfr inhibitor combination therapies
CN112143815B (zh) *	2020-11-25	2021-02-26	江苏申基生物科技有限公司	一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法
EP4340840A1 (en)	2021-05-19	2024-03-27	JANSSEN Pharmaceutica NV	Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
KR20240099258A (ko)	2021-10-12	2024-06-28	타리스 바이오메디컬 엘엘씨	에르다피티닙 제형 및 방광내 투여를 위한 시스템
TW202400174A (zh)	2022-02-18	2024-01-01	美商塔里斯生物醫學有限責任公司	用於膀胱內施用的Erdafitinib調配物及滲透系統
WO2024170495A1 (en)	2023-02-13	2024-08-22	Janssen Pharmaceutica Nv	Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2024173377A1 (en)	2023-02-13	2024-08-22	Taris Biomedical Llc	Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2024173716A1 (en)	2023-02-17	2024-08-22	Taris Biomedical Llc	Erdafitinib for intravesical administration for use in the treatment of bladder cancer
CN119219611A (zh) *	2024-12-03	2024-12-31	南京诺源医疗器械有限公司	用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2372990C (en)	1999-05-05	2007-06-19	Institut Curie	Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en)	1999-05-05	2006-11-14	Institut Curie	Means for detecting and treating pathologies linked to FGFR3
DE60328618D1 (de)	2002-10-01	2009-09-10	Epigenomics Ag	Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
US8124331B2 (en) *	2003-03-26	2012-02-28	Progenika Biopharma, S.A.	In vitro method to detect bladder transitional cell carcinoma
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
EP1659175A1 (en) *	2004-11-18	2006-05-24	Institut Curie	Alterations in seborrheic keratoses and their applications
BRPI0611375A2 (pt)	2005-05-23	2010-08-31	Novartis Ag	formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
WO2007061127A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
WO2007067968A2 (en)	2005-12-08	2007-06-14	Novartis Ag	Effects of inhibitors of fgfr3 on gene transcription
EP1918376A1 (en)	2006-11-03	2008-05-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
BRPI0807696A2 (pt)	2007-02-27	2014-05-27	Novartis Ag	Método de identificação de células que apresentam sensibilidade à modulação de sinalização mediada por um receptor do fator de crescimento de fibroblastos ou uma variante do mesmo
WO2008109369A2 (en)	2007-03-02	2008-09-12	Mdrna, Inc.	Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US8163923B2 (en)	2007-03-14	2012-04-24	Advenchen Laboratories, Llc	Spiro substituted compounds as angiogenesis inhibitors
CN103157400B (zh)	2007-06-21	2014-12-24	简·探针公司	用于将容器暴露于多个热区的仪器和方法
US8071338B2 (en)	2007-08-08	2011-12-06	Roche Molecular Systems, Inc.	Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
WO2013173485A1 (en)	2012-05-15	2013-11-21	Predictive Biosciences, Inc.	Detection of bladder cancers
WO2013173480A1 (en)	2012-05-15	2013-11-21	Predictive Biosciences, Inc.	Detection of bladder cancer recurrence
GB0718542D0 (en)	2007-09-22	2007-10-31	Univ Dundee	Targeted modulation of gene expression
TWI381848B (zh)	2008-10-20	2013-01-11	Imclone Llc	抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
WO2010111625A1 (en)	2009-03-27	2010-09-30	Zymogenetics, Inc.	Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
WO2011027219A1 (en)	2009-09-04	2011-03-10	Progenika Biopharma, S.A.	High throughput detection of small genomic deletions and insertions
US9140689B2 (en) *	2010-03-14	2015-09-22	Translational Genomics Research Institute	Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
CN102293770A (zh) *	2011-05-25	2011-12-28	温州医学院	新型成纤维细胞生长因子受体酪氨酸激酶抑制剂
CN102319224B (zh) *	2011-07-27	2013-03-20	赛乐医药科技(上海)有限公司	复方甲氧那明的速释－缓释渗透泵制剂
MX2014001941A (es)	2011-08-18	2016-04-28	Nestec Sa	Composiciones y metodos para detectar variantes alelicas.
EP2761300A4 (en)	2011-09-27	2015-12-02	Univ Michigan	Recurrent genital fusion in breast cancer
AR088941A1 (es)	2011-11-23	2014-07-16	Bayer Ip Gmbh	Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (en) *	2011-12-12	2013-06-20	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
CA2866611C (en) *	2012-02-28	2020-01-07	Astellas Pharma Inc.	Nitrogen-containing aromatic heterocyclic compound
WO2013133351A1 (ja)	2012-03-08	2013-09-12	アステラス製薬株式会社	新規ｆｇｆｒ３融合体
US9254288B2 (en) *	2012-05-07	2016-02-09	The Translational Genomics Research Institute	Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209609D0 (en) *	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
JPWO2014007369A1 (ja) *	2012-07-05	2016-06-02	国立研究開発法人国立がん研究センター	Ｆｇｆｒ２融合遺伝子
JP6382194B2 (ja) *	2012-07-24	2018-08-29	ザトラスティーズオブコロンビアユニバーシティインザシティオブニューヨーク	融合タンパク質およびその方法
CN104487087A (zh)	2012-07-27	2015-04-01	基因泰克公司	治疗fgfr3相关疾患的方法
KR101942148B1 (ko) *	2012-09-27	2019-01-24	추가이 세이야쿠 가부시키가이샤	Ｆｇｆｒ３ 융합 유전자 및 그것을 표적으로 하는 의약
ES2949394T3 (es) *	2012-11-05	2023-09-28	Found Medicine Inc	Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) *	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
US9777333B2 (en)	2013-04-05	2017-10-03	Life Technologies Corporation	Gene fusion
WO2014193229A2 (en)	2013-05-27	2014-12-04	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Novel translocations in lung cancer
US9783853B2 (en)	2013-07-12	2017-10-10	The Regents Of The University Of Michigan	Recurrent gene fusions in cancer
UA122564C2 (uk)	2014-09-26	2020-12-10	Янссен Фармацевтика Нв	Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
US20200208224A1 (en)	2014-09-26	2020-07-02	Janssen Pharmaceutica Nv	Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar)	2017-02-06	2019-08-04	Janssen Pharmaceutica Nv	معالجة سرطان

2015
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/en active Pending
- 2015-09-18 CA CA2962075A patent/CA2962075A1/en active Pending
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 CN CN202111247854.6A patent/CN113957146A/zh active Pending
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 KR KR1020227040649A patent/KR20220162823A/ko active Search and Examination
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active IP Right Grant
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 MX MX2017003954A patent/MX2017003954A/es unknown
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/en active Application Filing
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/en active Active
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
2022
- 2022-03-23 IL IL291633A patent/IL291633A/en unknown
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending

Also Published As

Publication number	Publication date
IL251264B (en)	2022-04-01
KR102470456B1 (ko)	2022-11-23
AU2021277633A1 (en)	2021-12-23
MY194567A (en)	2022-12-02
CN113957146A (zh)	2022-01-21
CO2017003528A2 (es)	2017-07-11
CA2962075A1 (en)	2016-03-31
SMT202200177T1 (it)	2022-05-12
EP3198033B1 (en)	2022-02-16
JP2024112991A (ja)	2024-08-21
JP6766037B2 (ja)	2020-10-07
SV2017005415A (es)	2017-07-03
JP2020124192A (ja)	2020-08-20
CN107002141A (zh)	2017-08-01
JP7558216B2 (ja)	2024-09-30
BR112017006088A2 (pt)	2017-12-19
HRP20220496T1 (hr)	2022-05-27
EP3198033A2 (en)	2017-08-02
MX2022006536A (es)	2022-07-11
PH12017500556A1 (en)	2017-08-30
IL291633A (en)	2022-05-01
SG11201702381QA (en)	2017-04-27
TW201619609A (zh)	2016-06-01
ZA201702899B (en)	2019-06-26
ECSP17025787A (es)	2018-07-31
EP4063516A1 (en)	2022-09-28
MA40761B1 (fr)	2022-04-29
PL3198033T3 (pl)	2022-08-29
AU2021277633B2 (en)	2024-11-28
DK3198033T3 (da)	2022-04-11
AR102345A1 (es)	2017-02-22
GT201700059A (es)	2019-08-21
EA201790716A1 (ru)	2017-10-31
ES2912567T3 (es)	2022-05-26
MX2017003954A (es)	2017-12-14
NI201700035A (es)	2017-06-22
AU2015321626A1 (en)	2017-04-06
US20160090633A1 (en)	2016-03-31
US20190078166A1 (en)	2019-03-14
NZ730886A (en)	2024-08-30
AU2015321626B2 (en)	2021-12-16
IL251264A0 (en)	2017-05-29
CR20170104A (es)	2017-05-31
EA037920B1 (ru)	2021-06-07
RS63178B1 (sr)	2022-06-30
CN107002141B (zh)	2021-11-02
UY36325A (es)	2016-04-01
TWI706136B (zh)	2020-10-01
US12037644B2 (en)	2024-07-16
SI3198033T1 (sl)	2022-06-30
MA40761A (fr)	2017-08-01
US20240309463A1 (en)	2024-09-19
HUE058219T2 (hu)	2022-07-28
WO2016048833A3 (en)	2016-05-19
LT3198033T (lt)	2022-05-10
KR20220162823A (ko)	2022-12-08
JP7051920B2 (ja)	2022-04-11
WO2016048833A2 (en)	2016-03-31
CY1125190T1 (el)	2024-12-13
KR20170062495A (ko)	2017-06-07
UA122564C2 (uk)	2020-12-10
JP2017529090A (ja)	2017-10-05
JO3681B1 (ar)	2020-08-27
JP2022109910A (ja)	2022-07-28

Publication	Publication Date	Title
IL291633A (en)	2022-05-01	Use of fgfr mutant gene panels in identifying cancer patients who will respond to fgfr inhibitor treatment
IL260511B (en)	2022-03-01	Prodrugs of fumarates and their use in the treatment of various diseases
GB2592821B (en)	2022-01-12	Modified cells and methods of therapy
SG11201703257RA (en)	2017-05-30	Determination of water treatment parameters based on absorbance and fluorescence
SG11201703259UA (en)	2017-05-30	Determination of water treatment parameters based on absorbance and fluorescence
SG11201605506QA (en)	2016-08-30	Systems and methods for use of known alleles in read mapping
HK1218336A1 (zh)	2017-02-10	製作和展示電子書擴展內容的方法和裝置
IL268842A (en)	2019-10-31	Use of biomarkers in the identification of cancer patients who will respond to treatment with a PRMT5 inhibitor
HK1256118A1 (zh)	2019-09-13	Fgfr表達和對fgfr抑制劑的敏感性
IL252686A0 (en)	2017-08-31	Pyrazolopyridineamines as inhibitors of mknk1 and mknk2
SG10201709955PA (en)	2018-01-30	Methods of treatment and compositions with xanthine oxidase inhibitors
SG11201504771RA (en)	2015-09-29	Host cells and methods of use
SG11201603506PA (en)	2016-05-30	Treatment of damaged nerve with pten inhibitor
HUE055747T2 (hu)	2021-12-28	EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra
GB201417281D0 (en)	2014-11-12	Methods and devices relating to the detection of oral cancer biomarkers
EP3151821A4 (en)	2017-12-13	Marmelin analogs and methods of use in cancer treatment
EP3126521A4 (en)	2017-11-08	Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer
EP3212791A4 (en)	2018-10-17	Methods of detecting braf in cancer
SG11201609485RA (en)	2016-12-29	Detection of acrylic acid
PT2857023T (pt)	2016-07-11	Utilização de odiparcil no tratamento de uma mucopolissacaridose
EP3134547A4 (en)	2017-11-22	The tgf(beta)-mir200-mig6 pathway and its use in the treatment of cancer as an indicator of resistance to egfr inhibitors
AU360233S (en)	2015-02-06	Cord of window covering
GB201410695D0 (en)	2014-07-30	Uses of oligouronates in cancer treatment